Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

BACKGROUND AND AIMS: First generation protease inhibitors (PI) with peg-interferon (PEG-IFN) and ribavirin (RBV) have been the only therapy available for hepatitis C virus (HCV) genotype 1 infection in most countries for 3 years. We have investigated the efficacy and tolerance of this triple therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Coilly, Audrey, Dumortier, Jérôme, Botta-Fridlund, Danielle, Latournerie, Marianne, Leroy, Vincent, Pageaux, Georges-Philippe, Agostini, Hélène, Giostra, Emiliano, Moreno, Christophe, Roche, Bruno, Antonini, Teresa Maria, Guillaud, Olivier, Lebray, Pascal, Radenne, Sylvie, Saouli, Anne-Catherine, Calmus, Yvon, Alric, Laurent, Debette-Gratien, Maryline, De Ledinghen, Victor, Durand, François, Duvoux, Christophe, Samuel, Didier, Duclos-Vallée, Jean-Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578772/
https://www.ncbi.nlm.nih.gov/pubmed/26394142
http://dx.doi.org/10.1371/journal.pone.0138091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578772/
https://www.ncbi.nlm.nih.gov/pubmed/26394142
http://dx.doi.org/10.1371/journal.pone.0138091

Ejemplares similares